Nasdaq zyne.

Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.ZYNE Stock 12 Months Forecast. $1.11. (-14.62% Downside) Based on 3 Wall Street analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $1.11 with a high forecast of $1.11 and a low forecast of $1.11. The average price target represents a -14.62% change from the last price of $1.30 ...12 de dez. de 2017 ... ... (NASDAQ:AAPC) AbbVie, Inc. (NYSE:ABBV) Cara Therapeutics Inc. (NASDAQ ... (NASDAQ:ZYNE. Not sure if these are outdated, not really to savvy ...Links ZYNE StockTwits. Show Market Indexes. No Data. *** StockConsultant data not available for this stock. Consulting data available on NASDAQ, NYSE, and AMEX ...Zynerba Pharmaceuticals, Inc. (ZYNE.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Zynerba Pharmaceuticals, Inc. | …

November 20, 2023 at 1:14 PM PST. Listen. 1:51. The Nasdaq 100 Stock Index closed at the highest in nearly two years, with tech stocks gaining on high expectations for artificial …May 18, 2023 at 10:05 AM · 3 min read With the business potentially at an important milestone, we thought we'd take a closer look at Zynerba Pharmaceuticals, Inc.'s ( NASDAQ:ZYNE) future...

NASDAQ: Zynerba Pharmaceuticals Inc (ZYNE) = 1.30 USD. Provided by Alpha Vantage.

After-Hours Trades. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as ...Oct 4, 2023 · Please include the stock symbol for the offer (ZYNE) and the number of shares you would like to tender. Call Charles Schwab at 1-800-435-4000 Call Morgan Stanley at 1-888-454-3965 Один из главных продуктов компании – гель с каннабидиолом Zygel. Акции компании торгуются на бирже NASDAQ под тикером ZYNE. Дивиденды не выплачивались.DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and ...Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE) Under the terms of the Agreement, Zynerba will be acquired by Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq - HRMY). Harmony will ...

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment ...

Direct. 23,109. $0.00. 28,109. Back to ZYNE Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...

DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Jan 11, 2023 · Find the latest Earnings Report Date for Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com. DEVON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), please note that in the second paragraph of ...A downtrend has been apparent in Zynerba Pharmaceuticals (ZYNE) lately with too much selling pressure. The stock has declined 29.9% over the past four weeks. However, given the fact that it is now ...1,354,775. 260,365. 5.203368. Back to ZYNE Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...Nov 30, 2023 · Zynerba Pharmaceuticals (NASDAQ:ZYNE) Historical Stock Chart From Nov 2023 to Dec 2023 Zynerba Pharmaceuticals (NASDAQ:ZYNE) Historical Stock Chart From Dec 2022 to Dec 2023 Latest ZYNE Messages

DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics ...Aug 14, 2023 · Investor:Luis Sanay, CFA445-235-8386 [email protected]. Media:Cate McCanless 202-641-6086 [email protected]. Zynerba Pharmaceuticals Contact:Peter Vozzo ICR ... Real time Zynerba Pharmaceuticals (ZYNE) stock price quote, stock graph, news & analysis.Aug 14, 2023 · ZYNE Stock Gains on Promising Medicinal Marijuana Implications. A rare condition, fragile X syndrome affects about 1 in 4,000 males and 1 in 6,000 to 8,000 females in the U.S., according to the ... DEVON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) on Wednesday.. What Happened ...

Zynerba Pharmaceuticals (NASDAQ: ZYNE) reported R&D expenses of $5.1 million for the first quarter of 2022, including stock-based compensation of $0.5 million.

DEVON, Pa., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...14 de ago. de 2023 ... (NASDAQ: HRMY) announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) for $1.1059 per share in cash, or ...14 de ago. de 2023 ... Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) vio un incremento drástico en sus acciones el lunes después de que Harmony Biosciences (NASDAQ: ...DEVON, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics ...DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...Aug 14, 2023 · Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological ...

Nov 30, 2023 · Zynerba Pharmaceuticals (NASDAQ:ZYNE) Historical Stock Chart From Nov 2023 to Dec 2023 Zynerba Pharmaceuticals (NASDAQ:ZYNE) Historical Stock Chart From Dec 2022 to Dec 2023 Latest ZYNE Messages

DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...

Back to ZYNE Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ... Nasdaq Welcomes Nearly 40 Switches in 2021, Adding $361 Billion in Market Value to the Exchange Jan 18, 2022 Nasdaq Welcomes Nearly 70 Companies and 700 Investors to its 45th Investor Conference ...DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ...See All Market Activity. News + Insights. CLOSENasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency …Every investor in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see ...DEVON, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.DEVON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic ...DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...DEVON, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and ...DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...

DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Zynerba Pharmaceuticals Earnings Date and Reports 2023 (NASDAQ:ZYNE) Research Tools All Access Tools My MarketBeat My Portfolio My Performance My …Zynerba Pharmaceuticals Earnings Date and Reports 2023 (NASDAQ:ZYNE) Research Tools All Access Tools My MarketBeat My Portfolio My Performance My …Instagram:https://instagram. sofi student loan1976 to 1976 quarter valueoil companies to invest invanguard growth etfs Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the exploratory, open label Phase 2 INSPIRE (Assessing the Impact of Zygel [Transdermal CBD Gel] on Pediatric …With the business potentially at an important milestone, we thought we'd take a closer look at Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) future prospects. … how much money to start day tradingbest banks in illinois DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near ... sba corporation Company Profile. Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and ...DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan ...Find the latest Earnings Report Date for Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq.com.